Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Migraine With Aura Clear all
Completed Phase 3 Interventional Results available

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

NCT02605174
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine

NCT01828684
View directory record Official record
Conditions
Migraine Disorders, Photophobia
Interventions
Therapeutic Lens Coating, Sham Lens Coating
Other
Lead sponsor
Bradley Katz
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Adult Subjects With Acute Migraines

NCT03237845
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT05127954
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
109
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 23, 2026, 2:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Migraine and Body Composition

NCT01720862
View directory record Official record
Conditions
Migraine With and Without Aura, Chronic Migraine, Healthy Controls
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache

NCT00471952
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Maxalt 10mg MLT plus Caffeine 75mg, Maxalt 10mg MLT plus Placebo, Placebo + Placebo
Drug
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Jul 23, 2026, 2:21 PM EDT
Completed No phase listed Observational

The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras

NCT01080287
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

NCT03338920
View directory record Official record
Conditions
Acute Migraine With or Without Aura
Interventions
sumatriptan nasal powder, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Not applicable Interventional Results available

Transnasal Cooling for Migraine

NCT04936061
View directory record Official record
Conditions
Migraine, Episodic Migraine, Migraine With Aura, Migraine Without Aura
Interventions
CoolStat active device, CoolStat sham device
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • East Lansing, Michigan • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Not applicable Interventional Results available

PArtial REbreathing for Migraine With Aura 1

NCT05546385
View directory record Official record
Conditions
Migraine With Aura
Interventions
Partial Rebreathing Device, Sham breathing device
Device
Lead sponsor
Rehaler
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Palo Alto, California • Pasadena, California • Riverside, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Trial in Adult Subjects With Acute Migraines

NCT03461757
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
69
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT03874832
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura, Migraine
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Not applicable Interventional Results available

Cooling to Alleviate Migraine #3

NCT06874361
View directory record Official record
Conditions
Migraine With or Without Aura, Migraine, Migraine Headache
Interventions
Mi-Helper
Device
Lead sponsor
Mi-Helper, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Indian Harbour Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting Not applicable Interventional

A Comprehensive Digital Care Program for Migraine Management

NCT07642414
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Neuromodulation Wearable Device, Migraine Digital Care Program
Device · Other
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting Phase 3 Interventional

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
125
States / cities
Huntsville, Alabama • Saraland, Alabama • Glendale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting Phase 2 Interventional

Study of EVO756 in Adults With Migraine

NCT07616128
View directory record Official record
Conditions
Migraine
Interventions
EVO756, Dose 1, EVO756, Dose 2, Placebo
Drug
Lead sponsor
Evommune, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Los Angeles, California • Stamford, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Not applicable Interventional Results available

Evaluation of a Novel Device for Treatment of Migraine Headache

NCT03361423
View directory record Official record
Conditions
Migraine Without Aura, Migraine With Aura
Interventions
Nerivio Migra-1 active device, Nerivio Migra-1 Sham device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Hartford, Connecticut • Springfield, Missouri • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

NCT03901482
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebos
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
117
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety Study of DFN-15

NCT03006276
View directory record Official record
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

NCT00792636
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
49
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional

Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

NCT03061734
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02867709
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
109
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

NCT04100135
View directory record Official record
Conditions
Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
Interventions
Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel), Sham device PFO closure
Device · Drug
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Barbara, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

NCT03194555
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Low-Dose Naltrexone and Acetaminophen Combination, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Jul 23, 2026, 2:21 PM EDT